Geneuro

GeNeuro SA is a biotechnology company which develops novel medical therapies for inflammatory diseases involving Human Endogenous Retroviruses (HERV). Its initial therapeutic target is Multiple Sclerosis (MS), a progressive neurological disease involving loss of myelin from nerve cells, which is currently incurable and may lead to severe impairment.

GeNeuro is currently developing a new antibody with the potential to become the first treatment to stop the progression of Multiple sclerosis.

For more information, please visit www.geneuro.com